ASCRS clinical advisory on intracameral moxifloxacin injection for infection prophylaxis.
| Autor: | Myers WG; From the Northwestern University, Chicago, Illinois (Myers); University of California, San Francisco, San Francisco, California (Chang); Kaiser Permanente, Walnut Creek, California (Shorstein); Scripps Clinic Medical Group, La Jolla, California (Mah); Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah (Mamalis); Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California (Miller)., Chang DF, Shorstein NH, Mah FS, Mamalis N, Miller KM |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of cataract and refractive surgery [J Cataract Refract Surg] 2023 Oct 01; Vol. 49 (10), pp. 1068-1070. |
| DOI: | 10.1097/j.jcrs.0000000000001237 |
| Abstrakt: | Moxifloxacin solution is frequently injected at the conclusion of cataract surgery for endophthalmitis prophylaxis. 2 different concentrations are most commonly available in the United States for intracameral (IC) use: 0.5% (5 mg/mL) and 0.1% (1 mg/mL). The recommended volume to be injected is different for the 2 concentrations, and incorrect dosing can increase the risk of toxic anterior segment syndrome or endophthalmitis. In addition, the U.S. Food and Drug Administration recently published an alert regarding potential adverse events associated with intraocular compounded moxifloxacin. This clinical advisory reviews the optimal dosing of IC moxifloxacin based on current evidence. Competing Interests: Disclosures: W.G. Myers is a consultant and Medical Director at Leiters and a consultant and minority owner of Zion Therapeutics. None of the other authors has any relevant financial conflict of interests to report. (Copyright © 2023 Published by Wolters Kluwer on behalf of ASCRS and ESCRS.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|